Paid Clinical Trials Oakland

Discover 2,170 paid clinical trials in Oakland, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 2,170

Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Oakland CA, Berkeley CA, San Leandro CA, San Francisco CAshow 269 more

Code:

NCT05095376

Conditions

Glioblastoma

Gliosarcoma

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Lomustine

Magnetic Resonance Imaging

Photon Beam Radiation Therapy

Questionnaire Administration

Temozolomide

Mezigdomide & CarfilzomibA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Recruiting

PHASE3

Sponsor:

Bristol-Myers Squibb

Location:

Santa Rosa CA, Stockton CA, Los Angeles CA, Cerritos CAshow 34 more

Code:

NCT05552976

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Mezigdomide

Carfilzomib

Dexamethasone

AMT-162Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Recruiting

PHASE1

PHASE2

Sponsor:

UniQure Biopharma B.V.

Location:

San Francisco CA, Irvine CA, Fairway KS, Rochester MNshow 6 more

Code:

NCT06100276

Conditions

Amyotrophic Lateral Sclerosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AMT-162

AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Walnut Creek CA, San Jose CA, Long Beach CA, Anaheim CAshow 35 more

Code:

NCT05711394

Conditions

Episodic Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Atogepant

Placebo-Matching Atogepant

LuspaterceptA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Recruiting

PHASE3

Sponsor:

Celgene

Location:

Oakland CA, Stanford CA, Los Angeles CA, Houston TXshow 9 more

Code:

NCT04064060

Conditions

Myelodysplastic Syndromes (MDS)

Beta-thalassemia

Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Luspatercept

Orca-T, CAR T CellsMyeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL

Recruiting

PHASE1

Sponsor:

Melody Smith

Location:

Palo Alto CA

Code:

NCT05507827

Conditions

Lymphoid Leukemia

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)

Treg CD34+HSPC (Orca-T)

ICXP007Safety and Efficacy Study of ICXP007 With Compression Bandaging for the Treatment of Non-Infected Venous Leg Ulcers

Recruiting

PHASE3

Sponsor:

Intercytex

Location:

Alameda CA, San Francisco CA, Castro Valley CA, Sacramento CAshow 34 more

Code:

NCT00232973

Conditions

Leg Ulcer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ICXP007

Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting

PHASE2

Sponsor:

Allogene Therapeutics

Location:

Berkeley CA, Sacramento CA, Los Angeles CA, Duarte CAshow 33 more

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

PembrolizumabLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

San Francisco CA, Stanford CA, Fresno CA, Bakersfield CAshow 68 more

Code:

NCT03486873

Conditions

Solid Tumors

Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Standard of Care (SOC)

Lenvatinib

Olaparib

MK-4280

RavulizumabStudy of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Recruiting

PHASE3

Sponsor:

Alexion Pharmaceuticals, Inc.

Location:

San Francisco CA, Stanford CA, Los Angeles CA, Torrance CAshow 35 more

Code:

NCT06291376

Conditions

Immunoglobulin A Nephropathy

IgAN

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ravulizumab

Placebo